Study targets SGEF protein in treating glioblastoma brain tumors

January 13, 2016
Dr. Nhan Tran, is Associate Professor and head of TGen's Central Nervous System Tumor Research Lab and the study's senior author. Credit: TGen

The Translational Genomics Research Institute (TGen) has identified a protein called SGEF that promotes the survival of glioblastoma tumor cells and helps the cancer invade brain tissue.

TGen researchers identified SGEF as a target for new brain cancer therapies in a study published today by Molecular Cancer Research, a journal of the American Association for Cancer Research, the world's largest professional organization dedicated to advancing .

Glioblastoma multiforme, or GBM, is the most common primary tumor of the brain and central nervous system. One of the primary treatments for glioblastoma is surgical removal of the tumor. However, because of the aggressive way glioblastomas invade surrounding , it is impossible to remove all parts of the tumors, and the cancer eventually returns and spreads.

This study found that SGEF also plays a role in how glioblastoma tumors develop resistance to treatment. Following surgery, GBM is treated with radiation and the standard-of-care chemotherapy drug called temozolomide (TMZ),

"We need to identify the genetic and cellular-pathway signaling mechanisms that make resistant to treatment," said Dr. Nhan Tran, Associate Professor and head of TGen's Central Nervous System Tumor Research Lab. "And the role of SGEF in promoting chemotherapeutic resistance highlights this previously unappreciated protein. Importantly, this also suggests that SGEF could be a new candidate for development of targeted therapeutics," said Dr. Tran, the study's senior author.

This study was funded, in part, by The Ben & Catherine Ivy Foundation.

"Contributing to the progress, TGen studies are helping uncover the mysteries behind glioblastoma," said Catherine (Bracken) Ivy, founder and president of the Arizona-based Ben & Catherine Ivy Foundation. "This research is fundamental to helping patients survive longer and critical to our goal of improving treatments, and eventually finding a cure."

The ability of cancer cells to survive is influenced by the proteins that regulate cellular pathways involved in promoting how cells grow, replicate and spread, as well as whether cells will die when exposed to anti-cancer drugs. Radiation and drug treatment of GBM can lead to DNA damage. This study shows that SGEF promotes cancer cell survival in response to TMZ treatment by allowing tumor cells to rapidly repair the damaged DNA that otherwise would lead to cell death.

"Our study shows that SGEF may have an important role in helping cells survive injury—known as the pro-survival cellular signaling response—including injury to common drugs used to treat brain such as TMZ," said Dr. Shannon Fortin Ensign, the study's lead author.

"The roles of invasion and survival are interconnected in the promotion of disease progression," said Dr. Fortin Ensign, a former researcher at TGen who now is a resident in Internal Medicine at Scripps Green Hospital in La Jolla, Calif. "SGEF presents a novel hub in the interrelated axes of tumor cell invasion and survival."

The study, SGEF is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide, was published online today by AACR's Molecular Cancer Research.

Explore further: Team identifies drug that could limit the spread of deadly brain tumors

Related Stories

Team identifies drug that could limit the spread of deadly brain tumors

November 12, 2015
In a significant breakthrough, the Translational Genomics Research Institute (TGen) has identified a drug, propentofylline or PPF, that could help treat patients with deadly brain cancer.

New release of Glioblastoma Atlas sheds light on deadly disease

May 14, 2015
Robust new data added to the Ivy Glioblastoma Atlas Project (Ivy GAP) changes the scope and impact of this publicly available resource for researchers and clinicians searching for treatments for this most deadly and aggressive ...

Scientists find key driver for treatment of deadly brain cancer

January 8, 2016
Glioblastoma multiforme is a particularly deadly cancer. A person diagnosed with this type of brain tumor typically survives 15 months, if given the best care. The late Senator Ted Kennedy succumbed to this disease in just ...

Study identifies key protein that helps prevent lung cancer tumors from being destroyed

March 4, 2014
(Medical Xpress)—Researchers at the Translational Genomics Research Institute (TGen) have discovered a protein, Mcl-1, that helps enable one of the most common and deadly types of cancer to survive radiation and drug treatments.

Glioblastoma: Study ties three genes to radiation resistance in recurrent tumors

February 3, 2015
A new study identifies three genes that together enable a lethal form of brain cancer to recur and progress after radiation therapy.

Study provides comprehensive look at brain cancer treatments

May 1, 2015
Led by the Translational Genomics Research Institute (TGen) and UC San Francisco (UCSF), a comprehensive genetic review of treatment strategies for glioblastoma brain tumors was published today in the Oxford University Press ...

Recommended for you

Study suggests colon cancer cells carry bacteria with them when they metastasize

November 24, 2017
(Medical Xpress)—A team of researchers working at Harvard University has found evidence that suggests a certain type of bacteria found in colon cancer tumors makes its way to tumors in other body parts by traveling with ...

Promising new treatment for rare pregnancy cancer leads to remission in patients

November 24, 2017
An immunotherapy drug can be used to cure women of a rare type of cancer arising from pregnancy when existing treatments have failed.

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.